PP
PMVP icon

PDT Partners’s PMV Pharmaceuticals PMVP Stock Holding History

PDT Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-41,988
Closed -$258K – 645
2023
Q3 		$258K Sell
41,988
-7,725
-16% -$53.1K 0.03% 494
2023
Q2 		$311K Sell
49,713
-38,565
-44% -$202K 0.04% 448
2023
Q1 		$421K Buy
88,278
+21,945
+33% +$154K 0.06% 412
2022
Q4 		$577K Buy
66,333
+47,470
+252% +$506K 0.09% 359
2022
Q3 		$224K Buy
+18,863
New +$273K 0.03% 680
2021
Q4 		– Sell
-8,610
Closed -$257K – 987
2021
Q3 		$257K Buy
+8,610
New +$275K 0.02% 632

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PDT Partners's PMVP Position: Q4 2023 in Review

PDT Partners sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 41,988 shares — an estimated $258K sold.

PDT Partners first reported a position in PMVP in Q3 2021 and held it in 6 quarters. The position peaked at $577K in Q4 2022. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • PDT Partners reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • PDT Partners sold 41,988 PMV Pharmaceuticals shares in Q4 2023, an estimated $258K.
  • PDT Partners first reported a position in PMV Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • PDT Partners's PMV Pharmaceuticals position peaked at $577K in Q4 2022.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on PDT Partners's 13F filing for Q4 2023, filed 14 Feb 2024.